Biopharma staffers exhausted and susceptible to burnout, report says
Fierce Pharma
MAY 24, 2023
Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Fierce Pharma
MAY 24, 2023
Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52
Fierce Pharma
DECEMBER 20, 2022
2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MAY 16, 2023
FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41
Fierce Pharma
APRIL 18, 2023
Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48
Fierce Pharma
SEPTEMBER 7, 2023
Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.
Fierce Pharma
MAY 16, 2024
The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year.
Fierce Pharma
MARCH 21, 2023
Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14
Fierce Pharma
MAY 22, 2023
Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04
MedCity News
DECEMBER 15, 2022
2023 is shaping up to be a crucial year for everyone involved – and affected – by the pharmaceutical industry. It’s likely to be a year of experimentation for payers – and defensiveness for drug makers.
MedCity News
JANUARY 8, 2025
Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
Fierce Pharma
DECEMBER 22, 2023
Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.
Fierce Pharma
MAY 18, 2023
The Top Line': 2023's biopharma layoffs, plus this week's headlines tcarey Thu, 05/18/2023 - 16:13
MedCity News
MARCH 24, 2024
based pharma companies. The survey was conducted in late 2023 and results were reported this month. Lack of automation is the top challenge facing commercialization teams, according to a survey of executives at U.S.-based
Fierce Pharma
MAY 9, 2023
Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18
Fierce Pharma
APRIL 12, 2024
Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters. Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters.
Fierce Pharma
JANUARY 8, 2024
Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |
Fierce Pharma
JANUARY 23, 2023
Call for nominations: The most influential people in biopharma in 2023 esagonowsky Mon, 01/23/2023 - 14:32
Fierce Pharma
JANUARY 16, 2024
2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. | A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields.
MedCity News
DECEMBER 29, 2022
Many pharma and medical device companies will look inward, with the goal of standardizing and modernizing even highly regulated activities. Here’s a closer look at some important industry trends for 2023.
Fierce Pharma
APRIL 19, 2023
Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39
Fierce Pharma
MAY 9, 2023
We want your stories: Biopharma's collective memory of COVID—in photographs aliu Tue, 05/09/2023 - 14:56
Fierce Pharma
MAY 25, 2023
The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21
Fierce Pharma
JANUARY 3, 2024
Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk (..)
Fierce Pharma
FEBRUARY 21, 2024
In a year that started with more than two-thirds of biopharma companies posting | While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis.
Fierce Pharma
NOVEMBER 22, 2022
2023 preview: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation'. esagonowsky. Tue, 11/22/2022 - 14:22.
European Pharmaceutical Review
SEPTEMBER 15, 2023
For its 20 th anniversary, more than 180 entries across 12 categories have been narrowed down to determine the finalists the upcoming CPHI Pharma Awards. Award winners will be revealed at a networking reception on the first day of CPHI Barcelona 2023, which is running from 24-26 October. Are you coming to the CPHI Barcelona 2023?
MedCity News
APRIL 13, 2023
Rejection of Eli Lilly’s mirikizumab means that two of the four drugs the pharma giant identified as revenue growth drivers for 2023 have failed to pass the regulatory bar. One of those drugs has been approved while the fourth drug still awaits an FDA decision.
MedCity News
JANUARY 3, 2023
For EVOQ, the Gilead deal is its second with a big pharma company. Gilead Sciences is building up its autoimmune disease drug pipeline by turning to EVOQ Therapeutics, a startup with technology that takes a novel approach to restoring immune tolerance.
Pharma Pathway
FEBRUARY 28, 2023
Hetero Biopharma-Walk-In Interview for M.Sc/ B.Sc/ Diploma in Production On 4th Mar’ 2023 Job Description Greetings from Hetero Biopharma !!! Walk-In Interview for M.Sc/ B.Sc/ Diploma in Production @ Hetero Biopharma Department: Production Designation: Executive to Sr. 7-2-A2, Sanath Nagar, Opp.
European Pharmaceutical Review
FEBRUARY 21, 2023
Included in this issue of European Pharmaceutical Review : FOREWORD Accelerating drug development David Elder, David P Elder Consultancy RAMAN SPECTROSCOPY Shining a light on Raman for microbiological analysis Tim Sandle, Bio Products Laboratory LIMS Overcoming barriers to capturing data in a laboratory Samantha Kanza, University of Southampton ENVIRONMENTAL (..)
Pharma Pathway
FEBRUARY 23, 2023
Position: 26 Date: 26th Feb’ 2023 Time: 10:00 AM to 03:00 PM Venue: Celebrity Biopharma Limited, Vill -Panga Hilltop, Estate Via Jharmajri Distt. Celebrity Biopharma Limited (Aishwarya Group)-Walk-In Interviews for QA/ QC/ Production On 26th Feb’ 2023
MedCity News
OCTOBER 10, 2023
Merith Basey, executive director of Patients For Affordable Drugs, believes the Medicare price negotiation program is here to stay, no matter who is president and no matter how many Big Pharma players file lawsuits. among pretty much everyone who isn’t a pharma company, she said during a session at Engage at HLTH. Her reasoning?
European Pharmaceutical Review
JANUARY 23, 2025
1 all revenue in big pharma now come from dealmaking, confirming a need for robust inorganic growth and value creation strategies The year began with this forecast holding true, as the pharmaceutical industry declared major M&A deals including Johnson & Johnsons acquisition of Intra-Cellular Therapies, Inc.
PharmExec
OCTOBER 13, 2023
Exploring the pharma and biotech financing, M&A, and stock market pictures through the first half of 2023—and implications for the future, as market challenges continue to weigh heavily in senior management decision-making.
European Pharmaceutical Review
OCTOBER 2, 2023
CPHI Barcelona, the renowned global pharma event, is set to take centre stage from 24 to 26 October 2023 at Fira Barcelona Gran Via, Spain. CPHI creates connections and inspires partnerships across the global pharma community. CPHI creates connections and inspires partnerships across the global pharma community.
MedCity News
JANUARY 5, 2023
Fewer new drugs won FDA approvals in 2022 compared to previous years, but some of the products that passed regulatory muster are indicative of trends expected to continue into 2023. For example, more gene and cell therapies are on track to face regulatory decisions in the coming year.
European Pharmaceutical Review
DECEMBER 20, 2023
In Q1 2023, the European Commission (EC) announced proposed changes to EU pharmaceutical legislation. 1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. analysis (Source: L.E.K) What are the latest amendments?
MedCity News
DECEMBER 26, 2023
In the second half of 2023 alone, BMS has committed about $24 billion to business development deals. By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies.
European Pharmaceutical Review
AUGUST 24, 2023
This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted. Venture funding in 2022 came in at about $13.7 billion, down from the high of 2021.
MedCity News
NOVEMBER 27, 2022
The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.
MedCity News
MAY 22, 2023
Preliminary Phase 3 data are expected by the end of 2023. Ironwood Pharmaceuticals is paying $1 billion to acquire VectivBio, a biotech whose lead program could become a blockbuster treatment for a gastrointestinal disorder.
pharmaphorum
DECEMBER 23, 2022
And in 2023, these investments will hopefully pay off. With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. Marketing data will surpass health data as a leading signal for pharma advertisers.
MedCity News
JUNE 4, 2023
The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology. A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial.
MedCity News
MAY 3, 2023
GSK plans to launch Arexvy in time for the 2023/2024 RSV season. FDA approval of GSK’s respiratory syncytial vaccine Arexvy covers adults age 60 and older—an age group at particular risk of developing severe complications from infection.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content